March 14, 2022
Via: Drugs.comCorium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the U.S. Food and Drug Administration (FDA) has approved Corium’s Adlarity (donepezil transdermal system) as a treatment for patients with […]
March 30, 2023
March 28, 2023
March 23, 2023
March 16, 2023